Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
280.8 SEK | -0.43% | -0.92% | +5.17% |
Sales 2024 * | 24.52B 2.26B | Sales 2025 * | 27.15B 2.5B | Capitalization | 95.43B 8.79B |
---|---|---|---|---|---|
Net income 2024 * | 3.35B 309M | Net income 2025 * | 4.91B 453M | EV / Sales 2024 * | 4.49 x |
Net Debt 2024 * | 14.54B 1.34B | Net Debt 2025 * | 9.22B 849M | EV / Sales 2025 * | 3.85 x |
P/E ratio 2024 * |
28.6
x | P/E ratio 2025 * |
19.6
x | Employees | 1,752 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 50.87% |
Latest transcript on Swedish Orphan Biovitrum AB
1 day | -0.43% | ||
1 week | -0.92% | ||
Current month | -1.61% | ||
1 month | +6.53% | ||
3 months | -0.43% | ||
6 months | +22.83% | ||
Current year | +5.17% |
Managers | Title | Age | Since |
---|---|---|---|
Guido Oelkers
CEO | Chief Executive Officer | 59 | 17-05-21 |
Henrik Stenqvist
DFI | Director of Finance/CFO | 57 | 18-07-19 |
Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 68 | 20-12-31 | |
Annette Clancy
CHM | Chairman | 70 | 14-05-07 |
Staffan Schüberg
BRD | Director/Board Member | 55 | 19-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
1.15% | 0 M€ | +11.30% | ||
0.90% | 0 M€ | +11.04% | ||
0.69% | 0 M€ | +9.80% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-07 | 280.8 | -0.43% | 541,173 |
24-05-06 | 282 | +0.71% | 224,724 |
24-05-03 | 280 | 0.00% | 634,250 |
24-05-02 | 280 | -1.89% | 505,032 |
24-04-30 | 285.4 | +0.71% | 380,444 |
Delayed Quote Nasdaq Stockholm, May 07, 2024 at 11:29 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+5.17% | 8.87B | |
-2.47% | 88.14B | |
+3.29% | 40.44B | |
-15.40% | 32.24B | |
+51.96% | 24.39B | |
-14.35% | 15.59B | |
-39.65% | 12.3B | |
-6.52% | 12.18B | |
-13.41% | 12.14B | |
-6.67% | 8.41B |
- Stock Market
- Equities
- SOBI Stock